Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
recombinant human erythropoietin alfa · 1 trial · 3 indications
| Arm | Type | Description |
|---|---|---|
| placebo | PLACEBO_COMPARATOR | 50ml 0.9% NaCL |
| verum | ACTIVE_COMPARATOR | erythropoietin alfa 40,000 IU iv in 50ml 0.9% NaCl |
| Name | Type | Description |
|---|---|---|
| recombinant human erythropoietin alfa | DRUG | 40,000 IU in 50ml 0.9% NaCl iv on 3 consecutive days, starting within 6 hours after onset of symptoms |
| 0.9% NaCl | DRUG | 50ml 0.9% NaCl iv on 3 consecutive days, starting within 6 hours after onset of symptoms |
Inclusion Criteria: * Ischemic stroke in the middle cerebral artery territory * Clearly defined time of onset * Confirmed by MRI (DWI, Flair) * NIH Stroke Scale ≥ 5 * Age \> 18 years * Treatment within 6h after onset of symptoms * Informed consent by patient, relatives or independent physician * Li...
Recombinant human erythropoietin alfa is being studied for use in infarction of the middle cerebral artery, a type of acute ischemic stroke. It is an investigational therapy in Phase 2 clinical development for this neurological condition, and it is not yet approved for this use.
Recombinant human erythropoietin alfa is being developed by Johnson & Johnson, a company traded on the New York Stock Exchange under the ticker JNJ. The company is conducting clinical research to evaluate the drug's safety and efficacy for acute ischemic stroke.
Recombinant human erythropoietin alfa is in Phase 2 clinical development for infarction of the middle cerebral artery. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being evaluated in clinical trials.
Recombinant human erythropoietin alfa has one completed clinical trial, registered as NCT00604630. This Phase 2 study, titled "Multicenter Efficacy Study of Recombinant Human Erythropoietin in Acute Ischemic Stroke," enrolled 522 participants in Germany and was a randomized, double-blind, placebo-controlled trial.
Recombinant human erythropoietin alfa is a form of erythropoietin, a hormone that stimulates red blood cell production. In this context, it is being investigated as a potential treatment for acute ischemic stroke, specifically infarction of the middle cerebral artery, rather than for anemia.